Literature DB >> 20734219

Meningioma mouse models.

Michel Kalamarides1, Matthieu Peyre, Marco Giovannini.   

Abstract

Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery. In order to gain new insights in meningioma biology and develop alternative treatments, several meningioma mouse models have been engineered during the past two decades. As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice. Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported. Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors. These discoveries have led to the creation of a genetically engineered model utilizing conditional mutagenesis to specifically inactivate the mouse Nf2 gene in arachnoidal cells, resulting in the formation of intracranial meningothelial hyperplasia and meningiomas and thus reproducing the main mechanism of human meningeal tumorigenesis. This powerful new technology significantly improves on prior models and may open avenues of investigation never before possible in meningioma research. We present here a review of current meningioma mouse models used in translational therapeutics with associated imaging and pre-clinical studies.

Entities:  

Mesh:

Year:  2010        PMID: 20734219     DOI: 10.1007/s11060-010-0331-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

1.  Heterotransplantation of human glioblastoma multiforme and meningioma to nude mice.

Authors:  M W Rana; H Pinkerton; H Thornton; D Nagy
Journal:  Proc Soc Exp Biol Med       Date:  1977-05

2.  Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.

Authors:  Brian T Ragel; Randy L Jensen; David L Gillespie; Stephen M Prescott; William T Couldwell
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

3.  Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth.

Authors:  A Medhkour; M Van Roey; R A Sobel; H J Fingert; J Lee; R L Martuza
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

4.  Prostaglandin D synthase (beta-trace) in meningeal hemangiopericytoma.

Authors:  M Kawashima; S O Suzuki; T Yamashima; M Fukui; T Iwaki
Journal:  Mod Pathol       Date:  2001-03       Impact factor: 7.842

5.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

6.  A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.

Authors:  Arie Perry; Ruma Banerjee; Christine M Lohse; Bette K Kleinschmidt-DeMasters; Bernd W Scheithauer
Journal:  Brain Pathol       Date:  2002-04       Impact factor: 6.508

7.  Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.

Authors:  Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

8.  Telomerase in intracranial meningiomas.

Authors:  L Boldrini; S Pistolesi; S Gisfredi; S Ursino; G Lupi; M Caniglia; R Pingitore; F Basolo; G Parenti; G Fontanini
Journal:  Int J Mol Med       Date:  2003-12       Impact factor: 4.101

9.  A novel model of intracranial meningioma in mice using luciferase-expressing meningioma cells. Laboratory investigation.

Authors:  Brian T Ragel; Isaac L Elam; David L Gillespie; Jeannette R Flynn; David A Kelly; David Mabey; Harvey Feng; William T Couldwell; Randy L Jensen
Journal:  J Neurosurg       Date:  2008-02       Impact factor: 5.115

10.  Establishment of an in vivo meningioma model with human telomerase reverse transcriptase.

Authors:  Theresa G Cargioli; Hasan C Ugur; Naren Ramakrishna; Jennifer Chan; Peter M Black; Rona S Carroll
Journal:  Neurosurgery       Date:  2007-04       Impact factor: 4.654

View more
  8 in total

1.  A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.

Authors:  Fares Nigim; Juri Kiyokawa; Alessandra Gurtner; Yoichiro Kawamura; Lingyang Hua; Ekkehard M Kasper; Priscilla K Brastianos; Daniel P Cahill; Samuel D Rabkin; Robert L Martuza; W Shawn Carbonell; Hiroaki Wakimoto
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

Review 2.  The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas.

Authors:  Christina-Katharina Fodi; Jens Schittenhelm; Jürgen Honegger; Salvador Guillermo Castaneda-Vega; Felix Behling
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

Review 3.  Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis.

Authors:  Julien Boetto; Matthieu Peyre; Michel Kalamarides
Journal:  Acta Neurochir (Wien)       Date:  2020-11-20       Impact factor: 2.216

Review 4.  Role of Merlin/NF2 inactivation in tumor biology.

Authors:  A M Petrilli; C Fernández-Valle
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

5.  Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.

Authors:  D Bradley Welling; Katharine A Collier; Sarah S Burns; Janet L Oblinger; Edina Shu; Beth A Miles-Markley; Craig C Hofmeister; Mina S Makary; H Wayne Slone; Jaishri O Blakeley; S Alireza Mansouri; Brian A Neff; Robert K Jackler; Amir Mortazavi; Long-Sheng Chang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-08-20

Review 6.  Use of advanced neuroimaging and artificial intelligence in meningiomas.

Authors:  Norbert Galldiks; Frank Angenstein; Jan-Michael Werner; Elena K Bauer; Robin Gutsche; Gereon R Fink; Karl-Josef Langen; Philipp Lohmann
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

7.  An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors.

Authors:  Juan Sebastian Yakisich
Journal:  ISRN Pharmacol       Date:  2012-07-03

8.  Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.

Authors:  Stephen T Magill; Harish N Vasudevan; Kyounghee Seo; Javier E Villanueva-Meyer; Abrar Choudhury; S John Liu; Melike Pekmezci; Sarah Findakly; Stephanie Hilz; Sydney Lastella; Benjamin Demaree; Steve E Braunstein; Nancy Ann Oberheim Bush; Manish K Aghi; Philip V Theodosopoulos; Penny K Sneed; Adam R Abate; Mitchel S Berger; Michael W McDermott; Daniel A Lim; Erik M Ullian; Joseph F Costello; David R Raleigh
Journal:  Nat Commun       Date:  2020-09-23       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.